OUR SCIENCE

Alex co-founded Intrinsic Medicine and has served as our Chief Executive Officer and board member since August 2018 and as the Chairman of our Board of Directors since March 2021. From February 2018 until December 2018, he provided commercialization and corporate development consulting services to several drug development companies. Alex served as Director, Corporate Development of Ionis Pharmaceuticals, a biotechnology company headquartered in Carlsbad, California, specializing in developing RNA-targeted therapeutics, and in similar roles of increasing responsibilities where his contributions guided strategic planning, corporate development and research and development decision making over the seven years leading to February 2018. Previously, he co-founded and served as Director of Business Development and Legal Affairs and as a board member of a clinical-stage digital health company, and was an associate attorney with Wilson Sonsini Goodrich & Rosati, a U.S. law firm headquartered in Palo Alto specializing in business, securities and corporate law. He received his Juris Doctor from the University of Michigan Law School and his Bachelor of Arts in Health & Societies from the University of Pennsylvania.

Jason co-founded Intrinsic Medicine and has served as our President and board member since August 2018. From April 2018 until March 2020, he also provided intellectual property consulting services to early-stage drug development companies. Jason served in diverse management roles with Ionis Pharmaceuticals, including as Vice President, Regulatory Affairs and Corporate Development of Ionis Pharmaceuticals from May 2016 until April 2018, Vice President, Patents and Corporate Development from March 2012 to May 2016 and Vice President, Patents and Senior Patent Counsel from January 2009 until March 2012, as well as in various positions within the patent department from June 2004 until January 2009, including leading the department beginning in 2007. Before joining Ionis, he served as patent counsel for Enanta Pharmaceuticals, Inc. and patent manager for the Dana-Farber Cancer Institute. Prior to becoming an attorney, Jason was a research medicinal chemist. He received his Juris Doctor from Suffolk University Law School, cum laude, with an Intellectual Property Concentration with Distinction, his Master of Arts in Chemistry from San Diego State University, and his Bachelor of Science in Biochemistry with an emphasis in Chemistry from the University of California, Riverside.

Dr. Chuang is our Chief Medical Officer and has been with Intrinsic since September 2021. Dr. Chuang has worked as a consultant for Chuang Global Consulting, providing consulting services to companies in the life science industry since August 2016. Prior to joining Intrinsic Medicine, Dr. Chuang served as Vice President, Precision Medicine for Progenity, Inc., a biotechnology company developing molecular testing products and novel therapeutics, from July 2018 until December 2020, where he led the Clinical Translational and Clinical Operations departments, and was also an Officer of the company. Prior to that he served as Global Head of Translational Research and Early Clinical, Gastroenterology for Takeda Pharmaceuticals, a global biopharmaceutical company, from October 2016 until June 2018, where he was responsible for advancing early clinical assets to proof-of-concept stage of development. Dr. Chuang has served in numerous other leadership roles, including as Head of GI Clinical Development and Medical Affairs at Prometheus, where he worked on diagnostic and therapeutic products for patients with IBS and IBD. He joined Nestle Health Science in Switzerland following its acquisition of Prometheus in 2012, where for almost four years he helped develop Nestle’s strategy to bridge medical foods with therapeutics to deliver safer and efficacious products and was responsible for filing the first IND ever for a medical food. Dr. Chuang completed his GI and Nutrition training at Children’s Hospital of Philadelphia. He then joined the faculty at Duke University and the University of Pennsylvania before transitioning to the pharmaceuticals industry. He has authored over 70 peer-reviewed publications, abstracts and book chapters. Dr. Chuang received his medical degree at the University of Sydney and completed his pediatric specialty training in Australia before moving to the United States.

Dustin has served as our General Counsel and head of Corporate Development since September 2021, prior to which he consulted for the Company as the external head of Corporate Development since October 2020. Dustin practiced as an attorney in the mergers & acquisitions practice of Davis, Polk and Wardwell, an international law firm headquartered in New York City, from July until September 2021 and in the corporate and transactional practice of Hall, Estill, Hardwick, Gable, Golden & Nelson, P.C. a regional law firm headquartered in Tulsa, Oklahoma, from February 2020 until July 2021. Prior to joining Hall Estill, Dustin served as Senior Counsel and Assistant Corporate Secretary of SandRidge Energy, Inc., an energy company headquartered in Oklahoma City, Oklahoma, from July 2014 to February 2020 and, previously, in similar roles of increasing responsibilities with Chesapeake Energy Corporation. Prior to joining Chesapeake, Mr. Crawford began his legal career as an attorney in the finance practice in the New York office of Bracewell LLP (formerly Bracewell & Giuliani LLP) an international law firm headquartered in Houston, Texas. He received his Juris Doctor from Columbia Law School, where he was President and Editor-in-Chief of the Columbia Journal of Environmental Law, and his Bachelor of Science in Biochemistry, magna cum laude, from the University of Nevada, Las Vegas.